<DOC>
	<DOCNO>NCT00350857</DOCNO>
	<brief_summary>To examine safety effectiveness extended-release carbamazepine treatment child adolescent age 10-17 year acute manic mixed bipolar I disorder .</brief_summary>
	<brief_title>The Young Adult Pediatric Bipolar Study</brief_title>
	<detailed_description />
	<mesh_term>Carbamazepine</mesh_term>
	<criteria>Key 1 . DSMIV diagnosis bipolar I disorder , recent episode manic mixed . 2 . A lifetime history bipolar disorder symptom least 2 month . 3 . YMRS score great equal 16 . 4 . CGIS score great equal 4 . 5 . Male female outpatient age 1017 year old inclusive time consent . 6 . Functioning ageappropriate level intellectually , deem Investigator . 7 . The subject comorbid illness could affect efficacy , safety , tolerability way interfere subject 's participation study . 8 . Must satisfactory medical assessment clinically significant relevant abnormality . Key 1 . Current control uncontrolled , comorbid psychiatric diagnosis could interfere clinical assessment study conduct . 2 . A history lack therapeutic response hypersensitivity study drug . 3 . A great equal 50 % reduction YMRS Screening Baseline . 4 . Acutely risk suicidal violent behavior history suicide attempt require medical intervention . 5 . A history aplastic anemia , agranulocytosis bone marrow depression . 6 . A history seizure disorder , single childhood febrile seizure . 7 . A history severe , unstable asthma . 8 . Current hospitalization psychiatric symptom . 9 . History alcohol substance abuse dependence . 10 . Pregnant lactating female . 11 . Body weight less equal 25 kg .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2009</verification_date>
</DOC>